Immune check-point in glioblastoma multiforme. (June 2019)

• Record Type: Journal Article
• Authors: De Felice, F.; Pranno, N.; Marampon, F.; Musio, D.; Salducci, M.; Polimeni, A.; Tombolini, V.
• Is Part Of: Critical reviews in oncology/hematology. Volume 138(2019)
• Page Start: 60
• Page End: 69
• Publication Date: 2019-06
• Subjects: Glioblastoma -- Immune check-point -- Immunotherapy -- Survival -- Benefit; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2019.03.019
• Languages: English
• ISSNs: 1040-8428

Abstract

Highlights: The role of immune check-point inhibitors is being tested in glioblastoma multiforme (GBM). This is the largest updated analysis of preclinical and clinical trials in GBM. This analysis suggests that immune check-point inhibitors could influence outcomes in GBM. Abstract: Glioblastoma multiforme (GBM) represents one of the main frequent and aggressive primary brain neoplasms among adults worldwide. Despite a first-line multimodal treatment, including radical surgery and adjuvant radiation therapy with concomitant temozolomide-based chemotherapy, GBM prognosis continues to be unfavourable. During this decade, different research groups have explored immune check-point inhibitors role in order to improve response to therapy and subsequently prolong survival rate. The aim of this review was to analyze published literature to support immune check-point inhibitors use in the management of patients with GBM diagnosis. The hope was to help physicians for better decision-making.